<DOC>
	<DOCNO>NCT00015028</DOCNO>
	<brief_summary>The purpose study determine efficacy safety buprenorphine/naloxone sublingual tablet formulation office-based therapy opiate-dependence treatment . The developmental objective combination product expansion therapeutic option treatment opiate dependence .</brief_summary>
	<brief_title>Buprenorphine/Naloxone Opiate-Dependence Treatment - 1</brief_title>
	<detailed_description>This multicenter pivotal clinical trial comprise two phase . The first phase , four week length , double-blind placebo control primarily use evaluate efficacy buprenorphine/naloxone . The second phase , last 48 week , primarily conduct determine safety buprenorphine/naloxone .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>1 . DSMIV ( Diagnostic Statistical Manual American Psychiatric Association ) diagnosis current opiate dependence . 2 . Individuals seek opiatesubstitution pharmacotherapy opiate dependence . 3 . Males nonpregnant , nonnursing female , 18 59 year age ( inclusive ) . 4 . Individuals able give inform consent willing comply study procedure ( e.g. , provide urine sample observation , complete questionnaire ) . 1 . Any acute chronic medical condition would make participation study medically hazardous ( e.g. , acute hepatitis , unstable cardiovascular , hepatic , renal disease , unstable diabetes , symptomatic AIDS ; HIVseropositivity alone ) . 2 . Aspartate alanine aminotransferase ( AST , ALT ) level great three time upper limit normal . 3 . Individuals currently take systemic antiretroviral antifungal therapy . 4 . Current dependence ( DSMIV criterion ) psychoactive substance opiate , caffeine , nicotine . 5 . Current , primary , Axis I psychiatric diagnosis opiate , caffeine , nicotine dependence . 6 . Females childbearing potential agree use medically acceptable method birth control . Acceptable method include 1. oral contraceptive , 2. barrier ( diaphragm condom ) spermicide require due possibility local irritation allergic type reaction , recommend use , 3. levonorgestrel implant , 4. intrauterine progesterone contraceptive system , 5. medroxyprogesterone acetate contraceptive injection , 6. complete abstinence . 7 . Enrollment opiatesubstitution ( i.e. , methadone , levoalphaacetylmethadol ) treatment program within 45 day enrol present study . 8 . Individuals take ( licitly illicitly ) LAAM , methadone , naltrexone within day enrol present study . 9 . Individuals take buprenorphine , analgesic , within 365 day enrol present study . 10 . Participation investigational drug device study within 45 day enrol present study . 11 . Anyone , opinion site principal investigator , would expect complete first phase study protocol ( e.g. , due pending incarceration probable relocation clinic area ) .</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 1996</verification_date>
	<keyword>opioid dependence</keyword>
</DOC>